CONGRESS GUIDE

ERS International Congress 2016
DETAILED PROGRAMME
MONDAY 05 SEPTEMBER, 2016
PA2077
PA2078
PA2079
PA2080
PA2081
PA2082
PA2083
Blood pressure behavior in OSAS patients before and during CPAP determined by a continuously measuring cuff
less method
Gert Küchler (Randersacker, Germany), Gert Küchler, Jennifer Gehring, Andreas Patzak
Effect of central sleep apnoea on severity and short-term prognosis of acute coronary syndrome
Estefanía Galera Lozano (LLEIDA, Spain), Estefania Galera Lozano, Marina Florés, Jordi De Batlle, Alicia Sánchez-de-la-
Torre, Manuel Sánchez-de-la-Torre, Josep Maria Montserrat, Ferran Barbé
Timely association between obstructive sleep apnea (OSA) and cardiovascular outcome after first acute myocardial
infarction (AMI): A national wide population-based study
Ming-Tzer Lin (Taipei, Taiwan), Ming-Tzer Lin, Chi-Ling Chen, Pei-Lin Lee, Chi-Tai Fang
Obstructive sleep apnea and cardiovascular risk markers in community individuals- Results from the sleep apnea and
vascular evaluation (SAVE) study
Vanesa Loh (Singapore, Singapore), Vanesa Loh, Yan Yi Cheung, Siew Pang Chan, See Meng Khoo, Chi-Hang Lee,
Vanesa Loh
Protective cardiovascular effect of sleep apnea severity in obesity hypoventilation syndrome
Juan Fernando Masa Jiménez (Cáceres, Spain), Juan Fernando Masa Jiménez, M.-Ángeles Sánchez-Quiroga, Jaime Corral,
Auxiliadora Romero, Candela Caballero, Joaquín Terán-Santos, Maria L. Alonso-Álvarez, Teresa Gomez-Garcia, Mónica
González, Soledad López-Martinez, Pilar De Lucas, José M. Marin, Sergi Marti, Trinidad Díaz-Cambriles, Eusebi Chiner,
Erika Miranda, Carlos Egea, Ana Obeso, Babak Mokhlesi
Long-term effects of CPAP on blood pressure in non-resistant hypertensive patients with obstructive sleep apnea: A
30 month prospective study
Oana Claudia Deleanu (Bucarest, Romania), Oana Claudia Deleanu, Corina Ioana Oprea, Andra Elena Malaut, Ana Maria
Zaharie, Miruna Mihaela Micheu, Natalia Patrascu, Florin Dumitru Mihaltan
Adaptive servo-ventilation for central sleep apnea in systolic heart failure does not improve muscle sympathetic
nerve activity: A SERVE-HF substudy
Renaud Tamisier (GRENOBLE, France), Renaud Tamisier, Jean-Louis Pépin, Muriel Salvat, Holger Woehrle, Gilles
Barone-Rochette, Cécile Rocca, Helmut Teschler, Martin R. Cowie, Patrick Levy
PA2084
ServeHF in real life
Natascha Troester (Graz, Austria), Natascha Troester, Michael Palfner, Christoph Wohlkoenig, Martin Trinker, Markus
Dominco, Alexander Avian
Room ICC Capital Suite
10
Poster Discussion: IPF: from pathogenesis to treatment II
Chairs : Katerina Antoniou (Heraklion, Crete, Greece), Francesco Bonella (Dusseldorf, Germany)
Session 367 10:45 - 12:45
PA2085
PA2086
PA2087
PA2088
PA2089
PA2090
Diagnosis, treatment and attitudes about idiopathic pulmonary fibrosis in Latin American physicians
Ivan Cherrez Ojeda (Guayaquil, Ecuador), Ivan Cherrez Ojeda, Vincent Cottin, Juan Calderon, Erick Calero, Dayana
Cabrera, Annia Cherrez, Jose Martin Vilema
Clinical experience with nintedanib for the treatment of IPF in 80 cases
Maria Kontou (ATHENS, Greece), Maria Kontou, Velissaria Bousgou, Vasileios Tzilas, Evangelos Bouros, Stamatios
Tsipilis, Anreas Granitsas, Evangelos Marozanes, George Dionelis, Nikolaos Koulouris, Demosthenes Bouros
The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech
IPF registry
Monika Žurková (Olomouc, Czech Republic), Monika Zurková, Vítezslav Kolek, Vladimíra Loštáková, Eva Kriegová,
Martina Šterclová, Vladimír Bartoš, Martina Doubková, Ilona Binková, Michal Svoboda, Jana Strenková, Martina Placková,
Ladislav Lacina, Vladimir Rihak, František Petrík, Pavlína Lisá, Radka Bittenglová, Richard Tyl, Gustav Ondrejka, Hana
Suldova, Jaroslav Lnenicka, Jana Pšikalová, Tomáš Snízek, Jirí Homolka, Renata Králova, Jan Kervitzer, Martina Vašáková
Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience
Katleen Leceuvre (Kessel-lo, Belgium), Katleen Leceuvre, Els De Dycker, Tom Moerman, Jonas Yserbyt, Wim Wuyts
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
HIROYUKI TANIGUCHI (Nisshin, Japan), Hiroyuki Taniguchi, Takashi Ogura, Yoshikazu Inoue, Manabu Akimoto, Arata
Azuma
Nintedanib for idiopathic pulmonary fibrosis (IPF): Data from the German compassionate use program (CUP)
Francesco Bonella (Dusseldorf, Germany), Francesco Bonella, Michael Kreuter, Lars Hagmeyer, Claus Neurohr, Claus
Keller, Martin J. Kohlhäufl, Joachim Müller-Quernheim, Katrin Milger, Antje Prasse
146 26.08.2016